Search results
Goldman Sachs cuts Maxeon Solar stock to sell, slashes target By Investing.com
Investing.com· 4 days agoOn Tuesday, Goldman Sachs adjusted its stance on Maxeon Solar Technologies Ltd. (NASDAQ:MAXN),...
Goldman: Falling rates will drive outperformance in this group of stocks
Investing.com· 4 days agoIn a note to clients Wednesday, analysts at Goldman Sachs (NYSE: GS ) predict a period of...
Goldman Sachs sees space for UK retail stocks rebound
Investing.com· 6 days agoGoldman Sachs sees space for UK retail stocks rebound
First Solar shares gain as Goldman Sachs raises target, keeps Buy rating By Investing.com
Investing.com· 5 days agoOn Monday, Goldman Sachs (NYSE:GS) updated its outlook on First Solar (NASDAQ:FSLR), increasing the...
Advisory Services Network LLC Trims Position in Goldman Sachs TreasuryAccess 0-1 Year ETF...
ETF DAILY NEWS· 4 days agoAdvisory Services Network LLC lessened its position in shares of Goldman Sachs TreasuryAccess 0-1 Year ETF (NYSEARCA:GBIL – Free Report) by 56.5% in the ...
Goldman Sachs added these 2 stocks to its conviction list in June By Investing.com
Investing.com· 5 days agoGoldman Sachs announced the June update for its "European Conviction List - Directors’ Cut" report...
NVIDIA stock retains Conviction Buy rating from Goldman By Investing.com
Investing.com· 5 days agoOn Monday, Goldman Sachs (NYSE:GS) maintained its Conviction Buy rating and a $1,200.00 price target...
Goldman Sachs Has Potential For Alpha Generation: Analyst - Goldman Sachs Gr (NYSE:GS)
Benzinga· 5 days agoGoldman Sachs has a Buy rating and price target of $525; Shares declined by 0.9% to $452.47 at last...
Goldman Sachs recommends a specific trading strategy, naming 2 global 'conviction list' stocks
CNBC· 6 days agoGoldman Sachs recommended that investors consider a specific strategy when trading European markets...
Eli Lilly's Wegovy rival Zepbound will help make weight-loss drug market worth $130 billion by 2030,...
Business Insider via Yahoo Finance· 6 days agoZepbound is Eli Lilly's new weight-loss drug.Brendan McDermid/Reuters The anti-obesity drug market...